Barclays’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-23,200
| Closed | -$1.38M | – | 5065 |
|
|
2025
Q4 | $1.38M | Buy |
+23,200
| New | +$1.26M | ﹤0.01% | 3206 |
|
|
2025
Q3 | – | Sell |
-17,800
| Closed | -$978K | – | 5493 |
|
|
2025
Q2 | $978K | Hold |
17,800
| – | – | ﹤0.01% | 3352 |
|
|
2025
Q1 | $1.26M | Buy |
+17,800
| New | +$1.2M | ﹤0.01% | 2964 |
|
|
2024
Q4 | – | Sell |
-22,500
| Closed | -$1.58M | – | 5281 |
|
|
2024
Q3 | $1.58M | Sell |
22,500
-39,700
| -64% | -$3.32M | ﹤0.01% | 3043 |
|
|
2024
Q2 | $5.12M | Buy |
+62,200
| New | +$5.18M | ﹤0.01% | 1519 |
|
|
2024
Q1 | – | Sell |
-30,000
| Closed | -$2.89M | – | 5091 |
|
|
2023
Q4 | $2.89M | Buy |
+30,000
| New | +$2.65M | ﹤0.01% | 2600 |
|
|
2021
Q3 | – | Sell |
-21,400
| Closed | -$1.79M | – | 4751 |
|
|
2021
Q2 | $1.79M | Buy |
21,400
+9,800
| +84% | +$777K | ﹤0.01% | 2266 |
|
|
2021
Q1 | $876K | Sell |
11,600
-13,200
| -53% | -$1.08M | ﹤0.01% | 2855 |
|
|
2020
Q4 | $2.17M | Buy |
24,800
+20,000
| +417% | +$1.59M | ﹤0.01% | 2172 |
|
|
2020
Q3 | $365K | Sell |
4,800
-113,500
| -96% | -$11.5M | ﹤0.01% | 3454 |
|
|
2020
Q2 | $14.6M | Buy |
118,300
+72,200
| +157% | +$7.18M | 0.01% | 784 |
|
|
2020
Q1 | $3.9M | Buy |
46,100
+17,000
| +58% | +$1.46M | ﹤0.01% | 1681 |
|
|
2019
Q4 | $2.46M | Sell |
29,100
-18,300
| -39% | -$1.38M | ﹤0.01% | 2783 |
|
|
2019
Q3 | $3.19M | Buy |
47,400
+23,900
| +102% | +$1.84M | ﹤0.01% | 2318 |
|
|
2019
Q2 | $2.01M | Sell |
23,500
-1,200
| -5% | -$103K | ﹤0.01% | 2906 |
|
|
2019
Q1 | $2.19M | Sell |
24,700
-62,700
| -72% | -$5.81M | ﹤0.01% | 2471 |
|
|
2018
Q4 | $7.44M | Sell |
87,400
-59,300
| -40% | -$5.64M | 0.01% | 1334 |
|
|
2018
Q3 | $14.2M | Sell |
146,700
-13,400
| -8% | -$1.34M | 0.01% | 1049 |
|
|
2018
Q2 | $15.1M | Buy |
160,100
+44,500
| +38% | +$3.9M | 0.01% | 952 |
|
|
2018
Q1 | $9.37M | Sell |
115,600
-53,500
| -32% | -$4.59M | 0.01% | 1205 |
|
|
2017
Q4 | $15.1M | Buy |
169,100
+106,900
| +172% | +$9.3M | 0.01% | 956 |
|
|
2017
Q3 | $5.79M | Buy |
62,200
+47,300
| +317% | +$4.18M | 0.01% | 1424 |
|
|
2017
Q2 | $1.35M | Buy |
14,900
+400
| +3% | +$36.4K | ﹤0.01% | 2614 |
|
|
2017
Q1 | $1.27M | Sell |
14,500
-700
| -5% | -$62.3K | ﹤0.01% | 2514 |
|
|
2016
Q4 | $1.26M | Sell |
15,200
-34,600
| -69% | -$2.98M | ﹤0.01% | 2530 |
|
|
2016
Q3 | $4.61M | Sell |
49,800
-21,600
| -30% | -$2.03M | 0.01% | 1374 |
|
|
2016
Q2 | $5.55M | Buy |
71,400
+18,800
| +36% | +$1.6M | 0.01% | 1227 |
|
|
2016
Q1 | $4.31M | Sell |
52,600
-491,600
| -90% | -$40M | 0.01% | 1298 |
|
|
2015
Q4 | $56.6M | Buy |
544,200
+289,000
| +113% | +$30.2M | 0.07% | 244 |
|
|
2015
Q3 | $26.8M | Sell |
255,200
-8,900
| -3% | -$1.19M | 0.03% | 463 |
|
|
2015
Q2 | $35.9M | Buy |
264,100
+95,800
| +57% | +$11.9M | 0.04% | 407 |
|
|
2015
Q1 | $20.9M | Buy |
168,300
+73,100
| +77% | +$7.75M | 0.02% | 659 |
|
|
2014
Q4 | $8.57M | Buy |
95,200
+78,500
| +470% | +$6.53M | 0.01% | 1298 |
|
|
2014
Q3 | $1.2M | Sell |
16,700
-427,400
| -96% | -$28.1M | ﹤0.01% | 3139 |
|
|
2014
Q2 | $27.5M | Sell |
444,100
-121,100
| -21% | -$7.32M | 0.03% | 539 |
|
|
2014
Q1 | $38.4M | Buy |
565,200
+535,100
| +1,778% | +$39.4M | 0.04% | 380 |
|
|
2013
Q4 | $2.11M | Buy |
30,100
+10,600
| +54% | +$720K | ﹤0.01% | 2618 |
|
|
2013
Q3 | $1.4M | Sell |
19,500
-8,100
| -29% | -$538K | ﹤0.01% | 2965 |
|
|
2013
Q2 | $1.54M | Buy |
+27,600
| New | +$1.72M | ﹤0.01% | 2829 |
|
Other funds holding BMRN
VCM
VPM
Barclays's BMRN Position: Q1 2026 in Review
Barclays reduced its BioMarin Pharmaceuticals (BMRN) stake by 57% in Q1 2026, selling an estimated $9.66M and leaving 122,838 shares worth $6.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1634.
Barclays first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $510M in Q4 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Barclays held 122,838 shares of BioMarin Pharmaceuticals worth $6.94M as of Q1 2026.
- Barclays sold 165,709 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $9.66M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1634 holding.
- Barclays first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's BioMarin Pharmaceuticals position peaked at $510M in Q4 2023.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.